DC (dendritic cell) based breast cancer therapeutic vaccine and preparation method thereof
A therapeutic vaccine and breast cancer technology, applied in the fields of bioengineering and biomedicine, can solve the problems of poor tumoricidal ability and weak immune response, and achieve the effects of strong tumoricidal ability, promotion of antigen presentation, and stable traits.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
preparation example Construction
[0026] A kind of DC-based breast cancer therapeutic vaccine provided by the present invention, its preparation method comprises the following steps:
[0027] S1. Obtain immature DC;
[0028] S2. Co-cultivating the breast cancer antigen complex and the immature DC in the DC medium for 5-9 days; wherein, the breast cancer antigen complex is obtained by co-culturing the breast cancer cells and the MUC1 monoclonal antibody complex after extinguishing fire;
[0029] S3, then adding tumor necrosis factor-α to continue culturing until the DCs are mature and loaded with breast cancer antigen complexes.
[0030] In step S1, immature DCs can be derived from human blood, but since immature DCs only account for 0.5-1.0% of the total number of monocytes in the blood, the number is very small; therefore, in a preferred embodiment of the present invention, induction of monocytes Obtain immature DC by means of cells, the specific steps are:
[0031] S11, isolating mononuclear cells from per...
Embodiment 1
[0052] The preparation method of the breast cancer therapeutic vaccine based on DC comprises the following steps:
[0053] S1. Acquisition of breast cancer antigen complex:
[0054] S11. MCF-7 breast cancer cells in the logarithmic growth phase were purchased from the Hematology Hospital of the Chinese Academy of Medical Sciences;
[0055] S12. Inactivate the breast cancer cells in step S11 by freezing and thawing;
[0056] Take breast cancer cells in the logarithmic growth phase, wash them twice with normal saline, centrifuge at 1800 rpm, resuspend the cell solution in PBS solution, and obtain 1×10 7 cells / ml of breast cancer cell suspension, take 20 μL of cell suspension and add it to 100 μL of normal saline, then put it into liquid nitrogen, put it in a 37°C water bath after 5 minutes, and put it in again after the breast cancer cells are completely melted. In liquid nitrogen, repeat 3 times, then filter through a microporous membrane, collect the filtrate, and store it a...
Embodiment 2
[0068] The difference from Embodiment 1 provided by the present invention is that in this embodiment,
[0069] The concentration of immature DC was 2 × 10 5 a / ml;
[0070] The concentration of breast cancer cell suspension was 0.5×10 7 a / ml;
[0071] The concentration of MUC1 monoclonal antibody complex was 0.5 μg / (1×10 5 ) cells;
[0072] The concentration of tumor necrosis factor-α is 800U / ml;
[0073] The volume ratio of immature DC to breast cancer antigen complex was 4:1.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com